Evidence map›Paper›PMID 32000099›Full record

ArticleEpilepsy & behavior : E&B2020

Who is willing to participate in research? A screening model for an anxiety and depression trial in the epilepsy clinic.

Heidi M Munger Clary, Rachel D Croxton, Jonathan Allan, James Lovato, Gretchen Brenes, Beverly M Snively, Mingyu Wan, James Kimball, Matthew H Wong, Cormac A O'Donovan and 3 more

Open access · greenAbstract read
In one paragraph

Article in Epilepsy & behavior : E&B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. An aqueous extract ofHeliyon · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Reply to Braillon.Epilepsy & behavior : E&B · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Heidi M Munger ClaryDepartment of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: hmungerc@wakehealth.edu.
Rachel D CroxtonDepartment of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: croxrd13@alumni.wfu.edu.
Jonathan AllanDepartment of Psychiatry, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: jallan@wakehealth.edu.
James LovatoDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: jlovato@wakehealth.edu.
Gretchen BrenesDepartment of Internal Medicine, Section of Geriatrics, Wake Forest University, Winston-Salem, NC, USA. Electronic address: gbrenes@wakehealth.edu.
Beverly M SnivelyDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: bmellen@wakehealth.edu.
Mingyu WanNeuroscience Graduate Program, Wake Forest University, Winston-Salem, NC, USA. Electronic address: miwan@wakehealth.edu.
James KimballDepartment of Psychiatry, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Matthew H WongDepartment of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Cormac A O'DonovanDepartment of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: odonovan@wakehealth.edu.
Kelly ConnerDepartment of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: kconner@wakehealth.edu.
Victor JonesDepartment of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Pamela DuncanDepartment of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: pduncan@wakehealth.edu.
Wake Forest University · US

Funding

Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Wake Forest Clinical and Translational Science AwardKL2TR001421 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MILLER, DAVID P · 2015 to 2023
$5.8M
Wake Forest NeuroNext Clinical Site (WAKENN)U24NS107197 · NINDS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Mustapha Ahmad Ezzeddine, Roy Ervin Strowd · 2018 to 2026
$3.2M
Enhancing Scientific Inquiry in Clinical Neurosciences Through Methodology TrainiR25NS088248 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COFFEY, CHRISTOPHER S., GUTMANN, LAURIE · 2014 to 2018
$2.3M
Affordability and Efficiency for COMprehensive Post-Acute Stroke Services (COMPASS)R01HS025723 · AHRQ · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSHNELL, CHERYL D, TROGDON, JUSTIN · 2018 to 2021
$1.6M
AHRQ HHS R01 HS025723NCATS NIH HHS KL2 TR001421NCATS NIH HHS UL1 TR001420NINDS NIH HHS R25 NS088248NINDS NIH HHS U24 NS107197
6 · The paper itself

Abstract

objectiveAnxiety and depression in epilepsy are prevalent, associated with poor outcomes, underrecognized, undertreated, and thus a key area of need for treatment research. The objective of this study was to assess factors associated with research participation among epilepsy clinic patients who screened positive for anxiety or depression. This was accomplished by characterizing clinical and psychiatric factors among patients seen in an epilepsy clinic and evaluating which factors were associated with consent for potential research participation, via a combined clinical and research screening model.

methodsIn a pragmatic trial of anxiety and depression treatment in epilepsy, individuals with a positive screen for anxiety and/or depression at a routine epilepsy clinic visit were invited to opt-in (via brief electronic consent) to further eligibility assessment for a randomized treatment study. Information on psychiatric symptoms and treatment characteristics were collected for dual clinical care and research screening purposes. Cross-sectional association of demographic, clinical, and psychiatric factors with opting-in to research was analyzed by multiple logistic regression.

resultsAmong N = 199 unique adults with a first positive screen for anxiety and/or depression among 786 total screening events, 154 (77.4%) opted-in to further potential research assessment. Higher depression scores and current treatment with an antidepressant were independently associated with opting-in to research (depression odds ratio (OR) = 1.13 per 1-point increase in Neurological Disorders Depression Inventory-Epilepsy (NDDI-E) score, p = 0.028, 95% confidence interval (CI): 1.01-1.26; antidepressant OR = 2.37, p = 0.041, CI: 1.04-5.41). Nearly half of the 199 individuals (43.7%) with anxiety and/or depression symptoms were already being treated with an antidepressant, and 46.7% were receiving neither antidepressant therapy nor mental health specialty care. One-quarter (24.1%) reported a past psychiatric hospitalization, yet only half of these individuals were receiving mental health specialty care. SIGNIFICANCE: Our results demonstrate a high willingness to participate in research using a brief electronic consent approach at a routine clinic visit. Adults with persistent anxiety or depression symptoms despite antidepressant therapy and those with higher depression scores were more willing to consider a randomized treatment study. This has implications for future study design, as individuals already on treatment or those with more severe symptoms are often excluded from traditional research designs. We also found a high burden of psychiatric disease and high prevalence of persistent symptoms despite ongoing antidepressant treatment.

Indexed as

AdultAmbulatory Care FacilitiesAntidepressive AgentsAnxietyBiomedical ResearchCross-Sectional StudiesDepressionEpilepsyFemaleHumansMaleMass ScreeningMiddle AgedPatient ParticipationProspective StudiesAntidepressive AgentsAnxietyDepressionEpilepsyPragmatic trialResearch participationTreatment

Identifiers

PMID32000099
PMCPMC7282472
OpenAlexW3004199259

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.